Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene‑1,3‑diol is a synthetic small molecule belonging to the benzisoxazole class of organic compounds. It acts as a potent inhibitor of heat shock protein HSP90-alpha (Hsp90), a molecular chaperone involved in the activation and stabilization of various signaling proteins. Inhibition of Hsp90 disrupts its chaperone function and can lead to degradation of client proteins important for cancer cell survival. This compound was identified through structure-based drug design and has demonstrated nanomolar inhibitory activity against Hsp90 in biochemical assays[1][5][7]. Its primary research application is as an experimental tool compound for studying Hsp90 inhibition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol.